AU2017341112B2 - Immunogenic arginase peptides - Google Patents

Immunogenic arginase peptides Download PDF

Info

Publication number
AU2017341112B2
AU2017341112B2 AU2017341112A AU2017341112A AU2017341112B2 AU 2017341112 B2 AU2017341112 B2 AU 2017341112B2 AU 2017341112 A AU2017341112 A AU 2017341112A AU 2017341112 A AU2017341112 A AU 2017341112A AU 2017341112 B2 AU2017341112 B2 AU 2017341112B2
Authority
AU
Australia
Prior art keywords
arg
leu
gly
arg1
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017341112A
Other languages
English (en)
Other versions
AU2017341112A1 (en
Inventor
Mads Hald Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of AU2017341112A1 publication Critical patent/AU2017341112A1/en
Application granted granted Critical
Publication of AU2017341112B2 publication Critical patent/AU2017341112B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017341112A 2016-10-07 2017-10-06 Immunogenic arginase peptides Active AU2017341112B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192794.2 2016-10-07
EP16192794 2016-10-07
PCT/EP2017/075443 WO2018065563A1 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Publications (2)

Publication Number Publication Date
AU2017341112A1 AU2017341112A1 (en) 2019-05-02
AU2017341112B2 true AU2017341112B2 (en) 2024-06-27

Family

ID=57123856

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017341112A Active AU2017341112B2 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Country Status (18)

Country Link
US (3) US10858642B2 (enExample)
EP (2) EP4406613A3 (enExample)
JP (1) JP7211938B2 (enExample)
KR (1) KR102674521B1 (enExample)
CN (1) CN109890399A (enExample)
AU (1) AU2017341112B2 (enExample)
DK (1) DK3522905T3 (enExample)
ES (1) ES2992031T3 (enExample)
FI (1) FI3522905T3 (enExample)
HR (1) HRP20241486T1 (enExample)
HU (1) HUE069077T2 (enExample)
IL (1) IL265805B2 (enExample)
LT (1) LT3522905T (enExample)
MX (1) MX2019003970A (enExample)
PL (1) PL3522905T3 (enExample)
PT (1) PT3522905T (enExample)
SI (1) SI3522905T1 (enExample)
WO (1) WO2018065563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3522905T3 (pl) 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
GB201815549D0 (en) * 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
US20250161422A1 (en) 2022-02-24 2025-05-22 Io Biotech Aps Arginase 2 vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
CA2836155A1 (en) 2004-10-29 2006-05-11 Board Of Trustees Of Michigan State University Protection against herbivores
PL3064579T3 (pl) 2008-10-31 2021-07-05 Aerase, Inc. Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PL3522905T3 (pl) * 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
CN109890838A (zh) * 2016-10-27 2019-06-14 Io生物技术公司 新的pdl2化合物

Also Published As

Publication number Publication date
WO2018065563A1 (en) 2018-04-12
EP4406613A3 (en) 2024-10-23
HUE069077T2 (hu) 2025-02-28
JP2019537562A (ja) 2019-12-26
MX2019003970A (es) 2019-12-05
CA3039510A1 (en) 2018-04-12
CN109890399A (zh) 2019-06-14
HRP20241486T1 (hr) 2025-01-03
JP7211938B2 (ja) 2023-01-24
SI3522905T1 (sl) 2025-02-28
PL3522905T3 (pl) 2025-01-07
KR102674521B1 (ko) 2024-06-11
US11981944B2 (en) 2024-05-14
IL265805B2 (en) 2024-08-01
KR20190077381A (ko) 2019-07-03
IL265805B1 (en) 2024-04-01
EP3522905B1 (en) 2024-09-25
US20210139877A1 (en) 2021-05-13
EP3522905A1 (en) 2019-08-14
EP4406613A2 (en) 2024-07-31
US20190338270A1 (en) 2019-11-07
US20240167013A1 (en) 2024-05-23
PT3522905T (pt) 2024-10-02
AU2017341112A1 (en) 2019-05-02
FI3522905T3 (fi) 2024-10-31
DK3522905T3 (da) 2024-10-21
LT3522905T (lt) 2024-11-11
IL265805A (en) 2019-06-30
US10858642B2 (en) 2020-12-08
ES2992031T3 (es) 2024-12-05

Similar Documents

Publication Publication Date Title
US20240167013A1 (en) Immunogenic arginase peptides
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
AU2019377983B2 (en) Immunogenic peptides with improved oxidoreductase motifs
US20250236658A1 (en) Pdl2 compounds
ES2510493T3 (es) Epítopos T CD4+ de la Survivina y sus aplicaciones
CN113966342A (zh) TGF-β疫苗
JP2022507373A (ja) 免疫原性アルギナーゼ2ポリペプチド
CN113906046A (zh) 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
HK40012895A (en) Immunogenic arginase peptides
HK40012895B (en) Immunogenic arginase peptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)